• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可切除胰腺癌患者术后血清 CA19-9 水平对预后的影响。

Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.

机构信息

Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan.

出版信息

Ann Surg Oncol. 2012 Feb;19(2):636-41. doi: 10.1245/s10434-011-2020-9. Epub 2011 Aug 24.

DOI:10.1245/s10434-011-2020-9
PMID:21863360
Abstract

BACKGROUND

Perioperative serum carbohydrate antigen 19-9 (CA 19-9) level has been reported to be a useful prognostic marker in pancreatic cancer. The object of this study was to investigate the predictive factors for survival, including preoperative and postoperative serum CA 19-9 levels in patients with pancreatic cancer.

METHODS

Between 2003 and 2009, a total of 269 patients with pancreatic invasive ductal carcinoma underwent macroscopically curative resection, and pre- and postoperative (within 3 months after surgery) serum CA 19-9 levels were evaluated in all of them. The prognostic significance of clinicopathologic factors was evaluated by univariate and multivariate analyses.

RESULTS

Preoperative serum CA 19-9 levels were higher than normal (>37 U/ml, 38-4600 U/ml) in 218 of 269 patients. Of these, after surgery, serum CA 19-9 level returned to within a normal range in 136 patients (62%), whereas 82 patients (38%) remained in the higher-than-normal range. In univariate and multivariate analyses, node metastasis (P < 0.001) and postoperative CA 19-9 level (>37 U/ml) (P < 0.0001) were independent predictors for poor survival. Postoperative CA 19-9 level was higher in patients with microscopically positive surgical margin (P = 0.02). Hepatic recurrence and peritoneal dissemination were associated with postoperative higher CA 19-9 level.

CONCLUSIONS

Postoperative CA 19-9 level was associated with positive surgical margin and hepatic or peritoneal recurrence and may be a useful predictor for survival in patients with pancreatic cancer.

摘要

背景

围手术期血清碳水化合物抗原 19-9(CA 19-9)水平已被报道为胰腺癌的一种有用的预后标志物。本研究的目的是探讨包括术前和术后血清 CA 19-9 水平在内的生存预测因素在胰腺癌患者中的应用。

方法

2003 年至 2009 年间,共有 269 例胰腺浸润性导管癌患者接受了宏观根治性切除术,所有患者均评估了术前和术后(术后 3 个月内)血清 CA 19-9 水平。采用单因素和多因素分析评估临床病理因素的预后意义。

结果

269 例患者中,218 例术前血清 CA 19-9 水平高于正常(>37 U/ml,38-4600 U/ml)。其中,136 例(62%)患者术后血清 CA 19-9 水平恢复正常范围,82 例(38%)患者仍处于高于正常范围。在单因素和多因素分析中,淋巴结转移(P<0.001)和术后 CA 19-9 水平(>37 U/ml)(P<0.0001)是不良生存的独立预测因素。手术切缘微阳性的患者术后 CA 19-9 水平较高(P=0.02)。肝复发和腹膜播散与术后 CA 19-9 水平升高有关。

结论

术后 CA 19-9 水平与手术切缘阳性、肝或腹膜复发有关,可能是预测胰腺癌患者生存的有用指标。

相似文献

1
Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.可切除胰腺癌患者术后血清 CA19-9 水平对预后的影响。
Ann Surg Oncol. 2012 Feb;19(2):636-41. doi: 10.1245/s10434-011-2020-9. Epub 2011 Aug 24.
2
Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.可切除胰腺癌患者围手术期血清 CA19-9 水平的预后影响。
Ann Surg Oncol. 2010 Sep;17(9):2321-9. doi: 10.1245/s10434-010-1033-0. Epub 2010 Mar 25.
3
Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.术前血清CA19-9及胰腺周围组织切缘作为胰腺癌长期生存的决定因素
Ann Surg Oncol. 2009 May;16(5):1231-40. doi: 10.1245/s10434-009-0415-7. Epub 2009 Mar 5.
4
The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.使用调整后的术前CA 19-9预测可切除胰腺癌的复发情况。
J Surg Res. 2007 Jun 1;140(1):31-5. doi: 10.1016/j.jss.2006.10.007. Epub 2007 Apr 9.
5
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.术前 CEA 和 CA 19-9 是可切除性胰腺导管腺癌患者生存的预后标志物——一项回顾性肿瘤标志物预后研究。
Int J Surg. 2013;11(10):1067-72. doi: 10.1016/j.ijsu.2013.10.005. Epub 2013 Oct 23.
6
[Factors influencing survival of patients with cancer of the pancreatic head after resection].[影响胰头癌患者切除术后生存的因素]
Zhonghua Zhong Liu Za Zhi. 2009 Jul;31(7):554-7.
7
The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.切缘状态和术后CA19-9水平对可切除胰腺癌术后大剂量放疗联合5-氟尿嘧啶同步化疗后生存及复发模式的影响。
Am J Clin Oncol. 2008 Oct;31(5):446-53. doi: 10.1097/COC.0b013e318168f6c4.
8
Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.术前血清C反应蛋白水平和术后淋巴结比率是胰腺导管腺癌胰十二指肠切除术后生存的重要预测指标。
JOP. 2012 Mar 10;13(2):199-204.
9
Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.血清CA 242在胰腺癌中的预后意义。与CA 19-9的比较。
Anticancer Res. 1995 Sep-Oct;15(5B):2181-6.
10
Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.术前血清CA 19-9水平检测不到与可切除胰腺腺癌患者生存率提高相关。
Ann Surg Oncol. 2004 Jul;11(7):644-9. doi: 10.1245/ASO.2004.11.025. Epub 2004 Jun 14.

引用本文的文献

1
Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer.胰腺癌新辅助治疗后以CA19-9降低定义的良好反应。
Ann Surg Oncol. 2025 Sep 1. doi: 10.1245/s10434-025-18084-0.
2
The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study.吉西他滨联合S-1辅助治疗可切除胰腺癌的临床疗效:一项单中心回顾性研究
BMC Cancer. 2025 Jul 22;25(1):1200. doi: 10.1186/s12885-025-14617-8.
3
Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma.
用于胰腺导管腺癌诊断和预后评估的分子生物标志物
J Pers Med. 2025 Jun 5;15(6):236. doi: 10.3390/jpm15060236.
4
Radiomics analysis of dual-layer detector spectral CT-derived iodine maps for predicting Ki-67 PI in pancreatic ductal adenocarcinoma.双层探测器光谱CT衍生碘图用于预测胰腺导管腺癌中Ki-67增殖指数的影像组学分析
BMC Med Imaging. 2025 Apr 17;25(1):124. doi: 10.1186/s12880-025-01664-7.
5
The Past, Present, and Future of Biomarkers for the Early Diagnosis of Pancreatic Cancer.胰腺癌早期诊断生物标志物的过去、现在与未来
Biomedicines. 2024 Dec 13;12(12):2840. doi: 10.3390/biomedicines12122840.
6
Molecular pathology and protein markers for pancreatic cancer: relevance in staging, in adjuvant therapy, in determination of minimal residual disease, and follow-up.胰腺癌的分子病理学与蛋白质标志物:在分期、辅助治疗、微小残留病的确定及随访中的相关性
Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):56-70. doi: 10.21037/hbsn-22-628. Epub 2023 Aug 14.
7
Development of a CT radiomics nomogram for preoperative prediction of Ki-67 index in pancreatic ductal adenocarcinoma: a two-center retrospective study.基于 CT 影像组学构建用于预测胰腺导管腺癌 Ki-67 指数的列线图:一项多中心回顾性研究。
Eur Radiol. 2024 May;34(5):2934-2943. doi: 10.1007/s00330-023-10393-w. Epub 2023 Nov 8.
8
Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist's Perspective.潜在可切除性胰腺导管腺癌的当前治疗:肿瘤内科医生的视角。
Cancer Control. 2023 Jan-Dec;30:10732748231173212. doi: 10.1177/10732748231173212.
9
Clinical Features and Outcomes of Patients with Pancreaticobiliary Malignancies in Los Angeles County and Their Association with CA 19-9 Levels.洛杉矶县胰胆管恶性肿瘤患者的临床特征与预后及其与CA 19-9水平的关联
Cancers (Basel). 2023 Mar 11;15(6):1723. doi: 10.3390/cancers15061723.
10
Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of abdominal radiology disease focus panel on PDAC.胰腺导管腺癌(PDAC)复发的术后监测:腹部放射学会PDAC疾病聚焦小组关于标准化成像和报告的实践模式
Abdom Radiol (NY). 2023 Jan;48(1):318-339. doi: 10.1007/s00261-022-03693-0. Epub 2022 Oct 14.